Roche says Lunsumio plus lenalidomide improves PFS in CELESTIMO
Roche announced phase III CELESTIMO results for Lunsumio (mosunetuzumab) plus lenalidomide versus MabThera/Rituxan (rituximab) plus lenalidomide in relapsed or refractory follicular lymphoma.